LA JOLLA, CALIF (November 7, 2022)
— Calidi Biotherapeutics, Inc. (Calidi), a
clinical-stage biotechnology company that is pioneering allogeneic
cell-based platforms to revolutionize oncolytic virus therapies, today
announced the presentation of new pre-clinical data from the company’s
SuperNova-1 (SNV1) platform at the upcoming Society for Immunotherapy of
Cancer (SITC) 37th Annual Meeting,
taking place in Boston, Massachusetts and virtually, November 8-12, 2022.
SNV1 is composed of adipose tissue-derived allogeneic stem cells
(AD-MSC) loaded with tumor-selective CAL1 oncolytic vaccinia virus that is
designed to overcome multiple innate and adaptive immune barriers that
restrict traditional oncolytic virotherapy. Early Calidi research has shown
the potential ability of the SNV1 platform to shield the viral payload from
the immune system, supporting efficient delivery to tumor sites and
effectively potentiating oncolytic viruses’ therapeutic efficacy.
The poster presentation details the evaluation of SNV1 in multiple
tumor-bearing mouse models, where SNV1 was tested for its ability to resist
humoral immune-mediated inactivation in cell culture. Additionally,
following either single or three dose regimens, tumor growth inhibition of
multiple human xenografts and murine syngeneic models was examined. The
study also investiagted the molecular signature associated with the
infection of mesenchymal stem cells (MSC) with the oncolytic virus CAL1 by
RNA sequencing.
“These incremental data validate our belief in the potential
of SNV1 and the use of stem cells as a delivery and potentiation platform
for oncolytic viruses,” said Antonio F. Santidrian, Ph.D., SVP, Global
Head of R&D of Calidi Biotherapeutics. “Through the demonstration
of tumor growth inhibition across multiple pre-clinical models as well as
the ability to overcome rapid inactivation by the immune system, we believe
SNV1 can revolutionize the use of oncolytic virotherapy to treat a broad
range of cancers and look forward to advancing this promising asset into the
clinic.”
Key highlights from the poster presentation are below:
- The SNV1 stem cell-based platform protects and potentiates
oncolytic vaccinia virus by circumventing humoral innate and adaptive
immune barriers, resulting in enhanced anticancer effects in
tumor-bearing mouse models.
- SNV1 provided instantly active viral particles for immediate
infection in the injected tumors, transforming the tumor environment
from “cold” to “hot” locally and systemically,
and leading to significant tumor growth inhibitions in multiple human
and mouse tumor models.
- Repeated intratumoral administrations of SNV1 inhibited
treated as well as distant untreated tumors. These effects were also
associated with a significant increase of tumor-infiltrating lymphocytes
in both treated and untreated tumors.
- RNA-sequenced genome-wide analysis provided insights into
the valuable role of stem cells in the immunotherapeutic MOA of SNV1.
Full details for the upcoming poster presentation are below:
Title: SuperNova1 (SNV1), a novel
oncolytic-cell based platform for cancer therapy
Abstract
ID: 1137
Location: Poster Hall
C
Date: November 10, 2022, 9:00 a.m. – 9:00
p.m. ET
Presenters: Duong H. Nguyen, Ph.D.,
Director of Translational Research and Innovation, and Antonio F.
Santidrian, Ph.D., Senior Vice President, Global Head of Research and
Development
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company
with proprietary technology that is revolutionizing the effective delivery
and potentiation of oncolytic viruses for targeted therapy against
difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent
allogeneic stem cell and oncolytic virus combination for use in multiple
oncology indications. Calidi’s off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses currently in development leading to enhanced efficacy and
improved patient safety. Calidi Biotherapeutics is headquartered in La
Jolla, California. For more information, please visit www.calidibio.com.
Contacts:
For Investors:
Stephen Jasper
stephen@gilmartinir.com